INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Corporate insider
RM

Rodman David Malcom

Chief Medical OfficerCIK 0001672659

EDGAR filingsOpen in network
Disclosed transactions50
Buys / sells0 / 16
Max Insider Score21
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
2,170 sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Mineralys Therapeutics, Inc.Chief Medical Officer · Jan 13, 2026
6
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$59K
2,170 sh
Aug 10, 2026
Aug 12, 2026
traded Aug 10, 2026
+2d
SEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,170 sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
4,167 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,438
417 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,542 sh
Jun 15, 2026Jun 17, 2026
traded Jun 15, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
417 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,167 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,542 sh
Jun 15, 2026Jun 17, 2026
traded Jun 15, 2026
+2dSEC FORM 4

Evidence

20
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$115K
4,584 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

15
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$235K
9,890 sh
Jun 15, 2026Jun 17, 2026
traded Jun 15, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
416 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

3
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$13K
416 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,423
416 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,167 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

4
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,349 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

10
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$176K
6,348 sh
Apr 15, 2026Apr 15, 2026
traded Apr 15, 2026
+0dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,542 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
4,167 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

13
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$373K
14.1K sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,542 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,857
6,349 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,170 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
2,170 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

6
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$59K
2,170 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

8
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$174K
6,348 sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,856
6,348 sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,167 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,542 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

3
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,348 sh
Mar 12, 2026Mar 16, 2026
traded Mar 12, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$7,038
253 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

1
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$84K
3,079 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

8
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$278K
10.7K sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
4,167 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,542 sh
Mar 13, 2026Mar 16, 2026
traded Mar 13, 2026
+3dSEC FORM 4

Evidence

4
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$66K
2,171 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
2,171 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,171 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,542 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC FORM 4

Evidence

21
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$252K
7,709 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC FORM 4

Evidence

21
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$371K
11.4K sh
Jan 14, 2026Jan 15, 2026
traded Jan 14, 2026
+1dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,542 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,167 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC FORM 4

Evidence

2
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
4,167 sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC FORM 4

Evidence

18
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$72K
2,170 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$6,856
6,348 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC FORM 4

Evidence

3
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,170 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,348 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC FORM 4

Evidence

18
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$205K
6,348 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC FORM 4

Evidence

0
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
2,170 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence